Ser1108
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteprivacy & cookiesCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Phosphorylation Site Page:
Ser1108 - eIF4G (rat)

Site Information
GGSGAKPsDTASEAT   SwissProt Entrez-Gene
Predicted information:  Scansite
Orthologous residues: eIF4G (human): S1106, eIF4G iso8 (human): (S1107), eIF4G iso2 (mouse): (S1096), eIF4G iso3 (human): (S1066), eIF4G (rabbit): (S909), eIF4G (mouse): (S1110)
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3290600

In vivo Characterization
Methods used to characterize site in vivo: phospho-antibody (1, 2), western blotting (1)
Relevant cell line - cell type - tissue: 'muscle, skeletal' (1, 2)

Controlled by
Treatments: indinavir (2), insulin (2), leucine (1), sepsis (1)



References

1

Vary TC (2007) Acute oral leucine administration stimulates protein synthesis during chronic sepsis through enhanced association of eukaryotic initiation factor 4G with eukaryotic initiation factor 4E in rats. J Nutr 137, 2074-9
17709445   Curated Info

2

Hong-Brown LQ, et al. (2005) Indinavir alters regulators of protein anabolism and catabolism in skeletal muscle. Am J Physiol Endocrinol Metab 289, E382-90
15827064   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.